| 1. |
Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(5): 541-565.
|
| 2. |
中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療指南(2022年版). 中華消化外科雜志, 2022, 21(2): 143-168.
|
| 3. |
Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol, 2018, 25(11): 3308-3315.
|
| 4. |
Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer, 2021, 10(4): 320-329.
|
| 5. |
梁斌, 張航宇, 馮健, 等. 累及下腔靜脈巨大肝癌轉化治療成功并根治性切除一例. 中華肝膽外科雜志, 2020, 26(4): 307-308, 309.
|
| 6. |
Kim HC, Lee JH, Chung JW, et al. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol, 2013, 24(2): 274-283.
|
| 7. |
Kim YJ, Jung J, Joo JH, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C. Radiother Oncol, 2019, 141: 95-100.
|
| 8. |
Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology, 2017, 66(2): 510-517.
|
| 9. |
van Lienden KP, van den Esschert JW, de Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol, 2013, 36(1): 25-34.
|
| 10. |
謝坤, 耿小平. 門靜脈栓塞在肝切除術前的臨床運用. 肝膽外科雜志, 2013, 21(6): 475-477.
|
| 11. |
Park GC, Lee SG, Yoon YI, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2020, 19(3): 244-251.
|
| 12. |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173.
|
| 13. |
張雯雯, 胡丙洋, 韓駿, 等. PD-1抑制劑與多靶點酪氨酸激酶抑制劑聯合方案用于進展期肝癌轉化治療研究的初步報告. 中華肝膽外科雜志, 2020, 26(12): 947-948.
|
| 14. |
胡丙洋, 張雯雯, 周黔川, 等. 巴塞羅那C期肝癌靶向聯合免疫降期轉化后實施左半肝切除術一例. 中華肝膽外科雜志, 2020, 26(1): 65-67.
|
